A Real-world Observational Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Colorectal Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The study is a real-world observational clinical study. Patients diagnosed as colorectal cancer through histopathology were screened and enrolled. Before anti-tumor treatment, colonoscopy biopsy tissue specimens, surgical specimens, and malignant pleural effusion or ascites specimens, etc. are collected. The investigators will perform a drug sensitivity testing based on a novel drug susceptibility testing method to test the commonly used anti-tumor treatment regimens. Patients were given conventional anti-tumor treatment according to the medical judgment of the doctors. Finally, the investigator will evaluate the consistency of clinical efficacy in colorectal cancer treatment and drug susceptibility outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Male or female, aged ≥ 18 and ≤80;

• Patients with colorectal cancer diagnosed by histopathology;

• Patients who need neoadjuvant treatment; adjuvant therapy after radical surgery or palliative treatment;

• Fresh tumor tissue specimens or malignant pleural effusion or ascites can be obtained;

• Patients who sign the informed consent form, and are able to comply with the study period treatment process.

Locations
Other Locations
China
Phase I Clinical Trials Center Of The First Hospital of China Medical University
RECRUITING
Shenyang
Contact Information
Primary
Shuhui Song, bachelor
593900927@qq.com
02483281137
Time Frame
Start Date: 2023-10-18
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 105
Sponsors
Collaborators: Precedo Pharmaceuticals Co. Ltd., Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China
Leads: Funan Liu

This content was sourced from clinicaltrials.gov